b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">31959021</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>27</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1746-045X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>15</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Expert opinion on drug discovery</Title>\n                <ISOAbbreviation>Expert Opin Drug Discov</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>New directions in antimalarial target validation.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>189-202</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/17460441.2020.1691996</ELocationID>\n            <Abstract>\n                <AbstractText><b>Introduction</b>: Malaria is one of the most prevalent human infections worldwide with over 40% of the world\'s population living in malaria-endemic areas. In the absence of an effective vaccine, emergence of drug-resistant strains requires urgent drug development. Current methods applied to drug target validation, a crucial step in drug discovery, possess limitations in malaria. These constraints require the development of techniques capable of simplifying the validation of <i>Plasmodial</i> targets.<b>Areas covered</b>: The authors review the current state of the art in techniques used to validate drug targets in malaria, including our contribution - the protein interference assay (PIA) - as an additional tool in rapid <i>in vivo</i> target validation.<b>Expert opinion</b>: Each technique in this review has advantages and disadvantages, implying that future validation efforts should not focus on a single approach, but integrate multiple approaches. PIA is a significant addition to the current toolset of antimalarial validation. Validation of aspartate metabolism as a druggable pathway provided proof of concept of how oligomeric interfaces can be exploited to control specific activity <i>in vivo</i>. PIA has the potential to be applied not only to other enzymes/pathways of the malaria parasite but could, in principle, be extrapolated to other infectious diseases.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Batista</LastName>\n                    <ForeName>Fernando A</ForeName>\n                    <Initials>FA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gyau</LastName>\n                    <ForeName>Benjamin</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Vilacha</LastName>\n                    <ForeName>Juliana F</ForeName>\n                    <Initials>JF</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bosch</LastName>\n                    <ForeName>Soraya S</ForeName>\n                    <Initials>SS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lunev</LastName>\n                    <ForeName>Sergey</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wrenger</LastName>\n                    <ForeName>Carsten</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Unit for Drug Discovery, Department of Parasitology, Institute of Biomedical Sciences, University of S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Groves</LastName>\n                    <ForeName>Matthew R</ForeName>\n                    <Initials>MR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Structural Biology Unit, XB20 Drug Design, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>20</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Expert Opin Drug Discov</MedlineTA>\n            <NlmUniqueID>101295755</NlmUniqueID>\n            <ISSNLinking>1746-0441</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Protein oligomerisation</Keyword>\n            <Keyword MajorTopicYN="N">drug target validation</Keyword>\n            <Keyword MajorTopicYN="N">malaria</Keyword>\n            <Keyword MajorTopicYN="N">phenotypic mapping</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>1</Month>\n                <Day>22</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31959021</ArticleId>\n            <ArticleId IdType="doi">10.1080/17460441.2020.1691996</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'